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Abstract
The prevalence and spectrum of germline mutations in BRCA1 and BRCA2 have been reported in 
single populations, with the majority of reports focused on Caucasians in Europe and North 
America. The Consortium of Investigators of Modifiers of BRCA1/2 (CIMBA) has assembled data 
on 18,435 families with BRCA1 mutations and 11,351 families with BRCA2 mutations 
ascertained from 69 centers in 49 countries on 6 continents. This study comprehensively describes 
the characteristics of the 1,650 unique BRCA1 and 1,731 unique BRCA2 deleterious (disease-
associated) mutations identified in the CIMBA database. We observed substantial variation in 
mutation type and frequency by geographical region and race/ethnicity. In addition to known 
founder mutations, mutations of relatively high frequency were identified in specific racial/ethnic 
or geographic groups that may reflect founder mutations and which could be used in targeted 
(panel) first pass genotyping for specific populations. Knowledge of the population-specific 
mutational spectrum in BRCA1 and BRCA2 could inform efficient strategies for genetic testing 
and may justify a more broad-based oncogenetic testing in some populations.
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BACKGROUND
Women who carry germline mutations in either BRCA1 [OMIM 113705] or BRCA2 
[600185] are at a greatly increased risk of breast and ovarian cancers. Estimates of cancer 
risk associated with BRCA1 and BRCA2 mutations vary depending on the population 
studied. For mutations in BRCA1, the estimated average risk of breast and ovarian cancers 
ranges from 57–65% and 20–50%, respectively (Chen and Parmigiani, 2007; 
Kuchenbaecker, et al., 2017). For BRCA2, average risk estimates range from 35–57% and 
5–23%, respectively (Chen and Parmigiani, 2007; Kuchenbaecker, et al., 2017). Mutation-
specific cancer risks have been reported that suggest breast cancer cluster regions (BCCR) 
and ovarian cancer cluster regions (OCCR) exist in both BRCA1 and BRCA2 
(Kuchenbaecker, et al., 2017; Rebbeck, et al., 2015). The identification of mutations in 
BRCA1 or BRCA2 has important clinical implications, as knowledge of their presence is 
important for risk assessment and informs medical management for patients. Interventions, 
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such as risk-reducing bilateral mastectomy and salpingo-oophorectomy or annual breast 
MRI screening, are available to women who carry deleterious BRCA1 or BRCA2 mutations 
to enable early detection of breast cancer and for active risk reduction by risk-reducing 
surgery (Domchek, et al., 2010; Rebbeck, et al., 2002; Saslow, et al., 2007). The presence of 
BRCA1 or BRCA2 mutations also can influence cancer treatment decisions, principally 
around the use of platinum agents or poly (ADP-ribose) polymerase (PARP) inhibitors (Lord 
and Ashworth, 2017) or contralateral risk-reducing mastectomy. Increasing numbers of 
women are having clinical genetic testing for BRCA1 and BRCA2 mutations, and 
recommendations continue to expand to whom testing should be offered (NCCN, 2017).
In whites drawn from the general populations in North America and the United Kingdom, 
the prevalence of BRCA1 and BRCA2 mutations has been estimated around a broad range 
from 0.1–0.3%, and 0.1–0.7%, respectively (Peto, et al., 1999; Struewing, et al., 1997; 
Whittemore, et al., 2004). The Australian Lifepool study, studying a control population 
consisting of cancer-free women ascertained via population-based mammographic screening 
program, estimated the overall frequency of BRCA1 and BRCA2 mutations to be 0.65% 
(1:153), with BRCA1 mutations at 0.20% (1:500) and BRCA2 mutations at 0.45% (1:222) 
(Thompson, et al., 2016). Estimates from the Exome Aggregation Consortium (ExAC) are 
similar, with frequencies of BRCA1 and BRCA2 mutations (excluding The Cancer Genome 
Atlas (TCGA) data) at 0.21% (1:480) and 0.31% (1:327), respectively; or combined at 
0.51% (1:195) (Maxwell, et al., 2016). As they do not include large genomic 
rearrangements, some newer population-based estimates may still under-represent the total 
number of BRCA1 and BRCA2 mutations. Although the overall prevalence of BRCA1 and 
BRCA2 mutations in most general populations is low, many hundreds of thousands of yet-
to-be-tested individuals worldwide carry these mutations.
The prevalence of founder mutations in some racial/ethnic groups is much higher. For 
example, the mutations BRCA1 c.5266dup (5382insC), BRCA1 c.68_69del (185delAG) and 
BRCA2 c.5946del (6174delT), have a combined prevalence of 2–3% in U.S. Ashkenazi 
Jews (Roa, et al., 1996; Struewing, et al., 1997; Whittemore, et al., 2004). For these 
mutations, double heterozygotes in BRCA1 and BRCA2 also have been reported (Friedman, 
et al., 1998; Moslehi, et al., 2000; Ramus, et al., 1997a; Rebbeck, et al., 2016). Several other 
founder mutations have been identified, including the Icelandic founder mutation BRCA2 c.
771_775del (999del5) (Thorlacius, et al., 1996); the French Canadian mutations BRCA1 c.
4327C>T (C4446T), and BRCA2 c.8537_8538del (8765delAG) (Oros, et al., 2006b; Tonin, 
et al., 1999; Tonin, et al., 2001); the BRCA1 mutations c.181T>G, and c.4034delA in 
Central-Eastern Europe (Gorski, et al., 2000); the BRCA1 c.548-4185del in Mexico 
(Villarreal-Garza, et al., 2015b; Weitzel, et al., 2013)(Villarreal-Garza, et al., 2015b; Weitzel, 
et al., 2013), the BRCA2 mutation c.9097dup in Hungary (Ramus, et al., 1997b; Van Der 
Looij, et al., 2000) and others. These mutations represent the majority of mutations observed 
in these populations and have been confirmed as true founder mutations as they have 
common ancestral haplotypes (Neuhausen, et al., 1996, 1998; Oros, et al., 2006a). Recurrent 
mutations have been identified in other populations, but they represent a smaller proportion 
of all unique BRCA1 and BRCA2 mutations, and have not been characterized as true 
founder mutations. There are multiple recurrent mutations in Scandinavian, Dutch, French, 
and Italian populations (Ferla, et al., 2007). Similarly, a number of recurrent mutations 
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specific to non-European populations also have been reported in Hispanic/Mexican, African-
American, Middle Eastern, and Asian populations (Bu, et al., 2016; Ferla, et al., 2007; 
Kurian, 2010; Lang, et al., 2017; Ossa and Torres, 2016; Villarreal-Garza, et al., 2015b).
The mutational spectra in BRCA1 and BRCA2 are best delineated in whites from Europe 
and North America. However, data on mutational spectra in non-white populations of Asian, 
African, Mediterranean, South-American and Mexican Hispanic descent have also been 
reported (Abugattas, et al., 2015; Ahn, et al., 2007; Alemar, et al., 2016; Bu, et al., 2016; 
Eachkoti, et al., 2007; Ferla, et al., 2007; Gao, et al., 2000; Gonzalez-Hormazabal, et al.; Ho, 
et al., 2000; Jara, et al., 2006; John, et al., 2007; Kurian, 2010; Laitman, et al.; Lang, et al., 
2017; Lee, et al., 2003; Li, et al., 2006; Nanda, et al., 2005; Ossa and Torres, 2016; Pal, et 
al., 2004; Rodríguez, et al., 2012; Seong, et al., 2009; Sharifah, et al.; Solano, et al., 2017; 
Song, et al., 2005; Song, et al., 2006; Toh, et al., 2008; Torres, et al., 2007; Troudi, et al., 
2007; Villarreal-Garza, et al., 2015b; Vogel, et al., 2007; Weitzel, et al., 2005; Weitzel, et al., 
2007; Zhang, et al., 2009). In the current study, we provide a global description of BRCA1 
and BRCA2 mutations by geography and race/ethnicity from the investigators of the 
Consortium of Investigators of Modifiers of BRCA1/2 (CIMBA).
METHODS
Details of centers participating in CIMBA and data collection protocols have been reported 
previously (Antoniou, et al., 2007). Details of the CIMBA initiative and information about 
the participating centers can be found at http://cimba.ccge.medschl.cam.ac.uk/h (Chenevix-
Trench, et al., 2007). All included mutation carriers participated in clinical or research 
studies at the host institutions after providing informed consent under IRB-approved 
protocols. Sixty-nine centers and multicenter consortia submitted data that met the CIMBA 
inclusion criteria (Antoniou, et al., 2007). Only female carriers with pathogenic BRCA1 
and/or BRCA2 mutations were included in the current analysis. One mutation carrier per 
family in the CIMBA database was included in this report. The actual family relationships 
(e.g., pedigrees) were not available, but a variable that defined family membership supplied 
by each center was used for this purpose. Less than 1% of families (86 of 29,700) had two 
family members with two different mutations. In these situations, each mutation observed in 
the family was included in the analysis. In the case of the 94 dual mutation carriers (i.e., 
individuals with both BRCA1 and BRCA2 mutations), one of the two mutations was chosen 
at random for inclusion in the analysis.
The CIMBA data set was used to describe the distribution of mutations by effect and 
function. For the remaining analyses, mutations were excluded if self-reported race/ethnicity 
data were missing. Pathogenicity of mutation was defined as follows: 1) generating a 
premature termination codon (PTC), except variants generating a PTC after codon 1854 in 
BRCA1 and after codon 3309 of BRCA2; 2) large in-frame deletions that span one or more 
exons; and 3) deletion of transcription regulatory regions (promoter and/or first exon) 
expected to cause lack of expression of mutant allele. We also included missense variants 
considered pathogenic by using multifactorial likelihood approaches (Bernstein, et al., 2006; 
Goldgar, et al., 2004). Mutations that did not meet the above criteria but have been classified 
as pathogenic by Myriad Genetics, Inc. (Salt Lake City, UT) also were included. 
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Classification of nonsense-mediated decay (NMD) was based on in-silico predictions and 
was not based on molecular classification (Anczukow, et al., 2008).
Contingency table analysis using a chi-square test was used to test for differences in 
dichotomous variables, as was a t-test for continuous variables. Mutation counts are 
presented as the number of families with the mutation. Fisher’s exact tests were used if 
sample sizes in any contingency table cell were less than five. Analyses were done in 
STATA, v. 14.2.
RESULTS
Mutations in BRCA1 and BRCA2
From the 26,861 BRCA1 and 16,954 BRCA2 mutation carriers in the CIMBA data set as of 
June 2017, 18,435 families with BRCA1 mutations and 11,351 families with BRCA2 
mutations were studied to count only one occurrence of a mutation per family. Figure 1 
shows the countries that contributed mutations to this report. From among these families, 
1,650 unique BRCA1 and 1,731 unique BRCA2 mutations were identified. The unique 
mutations and number of families in which each mutation was observed are listed in 
Supplementary Table 1. In each gene, the five most common mutations (including founder 
mutations) accounted for 33% of all mutations in BRCA1 (8,739 of 26,861 mutation 
carriers) and 19% of all mutations in BRCA2 (3,244 of 16,954 mutation carriers). A web 
site containing information about the most common mutations reported here can be found at: 
http://apps.ccge.medschl.cam.ac.uk/consortia/cimba/. This information may be periodically 
updated as new data become available.
Mutation Type and Effect
Table 1 presents a summary of the type of BRCA1 or BRCA2 mutations and their predicted 
effect on transcription and translation. The most common mutation type was frameshift 
followed by nonsense. The most common effect of BRCA1 and BRCA2 mutations was 
premature translation termination and most of the mutant mRNAs were predicted to undergo 
nonsense-mediated mRNA decay (NMD) (Anczukow, et al., 2008). Despite having the same 
spectrum of mutations in BRCA1 and BRCA2, the frequency distribution by mutation type, 
effect, or function differed significantly (p<0.05) between BRCA1 and BRCA2 mutation 
carriers for many groups, as shown in Table 1. These observed differences are largely 
because genomic rearrangements and missense mutations account for a much higher 
proportion of mutations in BRCA1 when compared with BRCA2, as previously described 
(Welcsh and King, 2001).
We and others have found that breast (BCCR) and ovarian (OCCR) cancer cluster regions 
exist that may confer differential cancer risks (Gayther, et al., 1997; Gayther, et al., 1995; 
Kuchenbaecker, et al., 2017; Rebbeck, et al., 2015). Figure 2 reports the relative frequency 
of mutations in the BCCR and OCCR by race/ethnicity. Compared with whites, we observed 
differences in the relative frequency of mutations in the BRCA1 BCCR and OCCR in Asians 
and Hispanics, and in the BRCA2 OCCR in Hispanics. To the degree that the mutations 
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within the BCCRs and OCCRs conferred differential cancer risks, these data suggest that 
BRCA1 and BRCA2 mutation-associated cancer risks may vary by race/ethnicity.
Geography and Race/Ethnicity
The most common mutations by country are summarized in Table 2 (BRCA1) and Table 3 
(BRCA2). The locations of the mutations that were observed in African American, Asian, 
and Hispanic populations are depicted in Figure 3 (BRCA1) and Figure 4 (BRCA2). Some 
countries (Albania, Bosnia, Costa Rica, Ireland, Honduras, Japan, Norway, Peru, 
Philippines, Qatar, Saudi Arabia, Romania, Venezuela and Turkey) contributed fewer than 
10 mutation carriers to the CIMBA database. Many of these mutations were submitted to the 
central database by CIMBA centers that ascertained these patients, but these patients 
originated from a different country. Based on such small numbers, it was impossible to make 
inferences about the relative importance of mutations in these locations. A description of the 
major ethnicity by country is provided in Supplementary Table 2.
The mutational distribution among the major racial/ethnic groups and by geography are 
summarized in Tables 4 and 5. Table 4 includes only those individuals for whom self-
identified race/ethnicity was recorded. Note that in some countries it is prohibited to collect 
data on race and ethnicity, so this information is missing. Among the 10 most common 
BRCA1 mutations in each racial/ethnic group, a few were seen in several populations, 
including the recurrent Jewish and Eastern European founder mutations c.5266dup 
(5382insC) and c.68_69del (185delAG); c.815_824dup in African-Americans and 
Hispanics; c.3756_3759del in Caucasian and Jews; and c.5503C>T and c.3770_3771del in 
Asians and Jews. Similarly, recurrent mutations in BRCA2 included c.5946del (6174delT) in 
whites and Jews; c.2808_2811del in whites, African Americans, Asians, Hispanics, and 
Jews; c.6275_6276del in whites and Hispanics; c.3847_3848del in whites and Jews; c.
658_659del in African Americans and Hispanics; and c.3264dup in Hispanics and Jews. The 
majority of other recurrent BRCA1 and BRCA2 mutations were only observed within a 
single racial/ethnic group, particularly African Americans, Asians, and Hispanics. Of note, 
the vast majority of women who self-identified as Jewish carry the Ashkenazi Jewish 
founder mutations BRCA1 c.5266dup and c.68_69del and BRCA2 c.5946del. Only 72 
(3.9%) of 1,852 BRCA1 mutation carrier families and 55 (5.6%) of 990 BRCA2 mutation 
carrier families who self-identified as being Jewish carried other (non-founder) mutations. 
However, since many individuals of self-identified Jewish ancestry are only tested for the 
three founder mutations, this number is likely to be underestimated.
In African Americans, the majority of BRCA1 mutations were not observed in any other 
racial/ethnic group, implying these mutations may be of African origin. In Hispanics, the 
most common BRCA1 mutations also were observed among individuals from other regions 
who did not self-identify as Hispanic, including BRCA1 c.3331_3334del (also observed in 
Australia, Europe, USA, and the UK), and BRCA1 c.68_69del (the Jewish founder 
mutation) (Weitzel, et al., 2013; Weitzel, et al., 2005). The BRCA1 c.815_824dup mutation 
has been reported as being of African origin, but has also been reported as a recurrent 
mutation in Mexican-Americans, perhaps as a reflection of the complex continental 
admixture of this population (Villarreal-Garza, et al., 2015b). BRCA1 c.390C>A and c.
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5496_5506delinsA were most commonly found in the Asian population. In BRCA2, c.
2808_2811del was found among the 10 most frequent mutations in all races/ethnicities.
Recurrent Mutations
As expected, the most common mutations in the entire data set were the founder mutations 
BRCA1 c.5266dup (5382insC), BRCA1 c.68_69del (185delAG), and BRCA2 c.5946del 
(6174delT). In part, the high frequency of these mutations is a consequence of panels that 
facilitate testing for these three mutations in women of Jewish descent. However, these two 
BRCA1 mutations also are relatively common in regions with a low proportion of 
individuals who self-identify as Jewish (e.g., Hungary, Czech Republic, France, Germany, 
Italy, Poland Spain, Russia, and UK). BRCA1 c.5266dup is a founder mutation thought to 
have originated 1800 years ago in Scandinavia/Northern Russia, entering the Ashkenazi-
Jewish population 400–500 years ago, and thus has origins and a spread pattern independent 
of the Ashkenazim (Hamel, et al., 2011). Haplotype studies have been used to determine the 
origin of BRCA1 c.68_69delAG in populations not considered to have a high proportion of 
Jewish ancestry. In some populations, such as the Hispanics in the USA and Latin American, 
it is associated with the Ashkenazi Jewish haplotype, presumably due to unrecognized 
(Jewish) ancestry (Ah Mew, et al., 2002; Velez, et al., 2012; Weitzel, et al., 2005). In other 
populations, such as Pakistani and Malaysians, where BRCA1 c.68_69del is a recurrent 
mutation, it appears to have arisen independently, as it is carried on a distinct haplotype 
(Kadalmani, et al., 2007; Rashid, et al., 2006). A different haplotype was also reported for 
several British families (the ‘Yorkshire haplotype’) that is distinct from both the Jewish and 
the Indian-Pakistani haplotypes (Laitman, et al., 2013; Neuhausen, et al., 1996).
The only locations in which these three founder mutations were not commonly observed 
were Belgium and Iceland. Iceland has another founder mutation (i.e., BRCA2 c.
771_775del). Yet other founder mutations included BRCA1 c.4327C>T and BRCA2 c.
8537_8538del in Quebec. This latter mutation in BRCA2 also is the most common mutation 
in high-risk families in Sardinia (Pisano, et al., 2000) and was also reported in a few Jewish 
Yemenite families, with a distinct haplotype(Palomba, et al., 2007). The BRCA1 c.181T>G 
mutation was observed in Central Europe (Austria, Czech Republic, Germany, Hungary, 
Italy and Poland), but also observed in the US, Argentina, Latvia, Lithuania and Israel. This 
mutation has been found on a common haplotype in individuals of Polish and Ashkenazi 
Jewish ancestry, suggesting it is an Eastern European founder mutation (Kaufman, et al., 
2009). The large rearrangement mutation in BRCA1 c.548-?4185+?del (ex9-12del) appears 
to be an important founder mutation in Mexico, with findings of a common haplotype and an 
estimated age at 74 generations (~1,500 years) (Weitzel, et al., 2013).
We observed a number of other recurrent mutations. BRCA1 c.3331_3334del comprised 
more than half of all mutations identified in Colombia, consistent with a previous report that 
this is a founder mutation in the Colombian population (Torres, et al., 2007). However, this 
mutation has not been found at high rates in a second Colombian population (Cock-Rada, et 
al., 2017). BRCA2 c.2808_2811del was frequently observed, not only as the most common 
mutation in France and Colombia, but also in other Western and Southern European 
countries, and destinations to which individuals from these countries have migrated. It 
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estimated to have arisen approximately 80 (46–134) generations ago. However, due to the 
diversity of the haplotypes, multiple independent origins could not be ruled out (Neuhausen, 
et al., 1998). BRCA2 c.6275_6276del was a recurrent BRCA2 mutation in Australia, the 
UK, Belgium, Spain, the Netherlands, and North America. This mutation has been estimated 
to have originated 52 (24–98) generations ago from a single founder (Neuhausen, et al., 
1998). Recurrent or founder mutations were observed in diverse populations. For example, 
the c.115T>G (Cys39Gly) mutation has been described in Greenlanders (Hansen, et al., 
2009). The c.2641G >T and c.7934del mutations have both been reported as founder 
mutation in South African Afrikaners (Reeves, et al., 2004).
DISCUSSION
We have reported worldwide distribution of BRCA1 and BRCA2 mutations curated in the 
CIMBA dataset. These results may aid in the understanding of the mutation distribution in 
specific populations as well as imparting clinical and biological implications for our 
understanding of BRCA1- and BRCA2-associated carcinogenesis.
Clinical testing for BRCA1 and BRCA2 mutations has benefited substantially from 
knowledge about common mutations in specific populations. In many countries, the three 
Ashkenazi-Jewish founder mutations are offered as a mutation testing panel for self-reported 
Ashkenazim, based on their frequency. This approach is much less expensive than 
comprehensive gene sequencing. The identification of commonly-occurring mutations in 
other populations could lead to more efficient and cost-effective mutation testing for BRCA1 
and BRCA2. For example, Villareal-Garza et al. (Villarreal-Garza, et al., 2015a) have 
developed the HISPANEL of mutations that optimizes testing in Hispanic/Latino 
populations. In the present study, we have identified mutations that may exist at a sufficient 
prevalence to warrant consideration for population-specific mutation testing panels. Criteria 
for developing such panels for BRCA1 and BRCA2 mutation screening are not available. 
However, mutations that are in a specific population and that capture a sufficient percentage 
of mutations in high risk individuals and families in that population may be appropriate for 
use in targeted genetic testing. Before such panels can be developed, population-based 
studies of mutation frequency in specific populations should be undertaken. The data 
reported herein provide a list of the recurrent mutations around which such panels could be 
developed, but the frequencies are not population-based, particularly in settings where 
founder mutations are preferentially screened (e.g., the Jewish founder panels). Similarly, 
putative founder mutations identified by assessing common ancestral origins of specific 
mutations (rather than just high prevalence; Table 5) may form the basis of population-
specific BRCA1 and BRCA2 mutation screening panels.
We report the distribution of BRCA1 and BRCA2 mutations in nearly 30,000 families of 
bona-fide disease-associated mutations. The strengths of this report include the large sample 
size that reflects a geographically and racially/ethnically diverse set of BRCA1 and BRCA2 
mutation carriers. However, some limitations need to be considered. First, the sample set 
presented here does not reflect a systematic study of these populations or races/ethnicities; 
the data reflect patterns of recruitment (e.g., individuals with higher risk or prior diagnosis 
of cancer who consented to participate in research protocols) that contributed to the CIMBA 
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consortium. Certain racial/ethnic or socio-demographic groups are under- or over-
represented or missing in our data set and, as a consequence, mutations may be over- or 
under-represented. For example, the existence of a commercial panel of three Jewish founder 
mutations enhances genetic testing for those mutations. As a result, the most frequently 
observed mutations in some populations (e.g., the USA) reflect the widespread use of this 
testing panel in the USA population. Similar arguments may also apply for other 
populations, where testing for certain founder mutations may be more frequent. Therefore 
the relative frequencies of mutations by population in the present study may be subject to 
such testing biases. Comparing the relative frequencies is also complicated by the inclusion 
of related individuals.
Second, although the CIMBA data represent most regions around the world, there are 
limitations related to which groups of individuals have been tested and which centers 
contributed data. In particular, non-white ancestry populations are still under-represented in 
research reports of mutation spectrum and frequency. Genetic testing in the developing 
world remains limited.
Third, we presented the mutations in terms of type or effect (Table 1), but these designations 
are not always based on experimental evidence. For example, NMD mutation status is 
almost always defined by a prediction rule rather than in vitro experiments that confirm the 
presence of nonsense mediated decay.
Fourth, we presented the occurrence of putative founder mutations. Some of these founder 
mutations (e.g., BRCA1 c.68_69del, BRCA2 c.771_775del) have been demonstrated to be 
true founder mutations based on actual ancestry analyses. Others, however, have only been 
identified as occurring commonly in certain populations, but haplotype or similar analyses 
of founder status may not have been done.
Fifth, our analysis was based on self-reported race/ethnicity of study participants, but this 
information may misclassify some groups of individuals. For example, some Middle Eastern 
groups may have been classified as “Caucasian” based on the data available, but in fact may 
represent a distinct group that was not captured here. Moreover, in some large centers 
participating in CIMBA, collecting information on race/ethnicity is prohibited and these 
mutation carriers were excluded from the comparisons.
Finally, we evaluated mutations by racial/ethnic and geographic designations, but some of 
these may be misclassified. For example, while BRCA1 c.68_69del has been shown to arise 
independently of the Jewish founder mutation in Pakistan (Rashid, et al., 2006), we cannot 
determine if the identified group also contains some Ashkenazi Jewish individuals.
The data presented herein provide new insights into the worldwide distribution of BRCA1 
and BRCA2 mutations. The identification of recurrent mutations in some racial/ethnic 
groups or geographical locations raises the possibility of defining more efficient strategies 
for genetic testing. Three Jewish founder mutations BRCA1 c.5266dup (5382insC) and 
BRCA1 c.68_69del (185delAG) and BRCA2 c.5946del (6174delT) have long been used as a 
primary genetic screening test for women of Jewish descent. The identification here of other 
recurrent mutations in specific populations may similarly provide the basis for other 
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mutation-specific panels. For example, BRCA1 c.5266dup (5382insC) may be a useful as a 
single mutation screening test in Central-Eastern European populations before undertaking 
full sequencing. However, this basic test may be supplemented with screening for BRCA1 c.
181T>G, as the second most common mutation of the region, and for some special cases, to 
include most common Hungarian BRCA2 founder mutation c.9097dup (9326insA) for those 
with Hungarian ancestry (van der Looij, et al., 2000, Ramus, et al., 1997b). In Iceland, only 
two mutations were reported: the founder mutation BRCA2 c.771_775del and the rarer 
BRCA1 c.5074G>A (Bergthorsson, et al., 1998). A number of other situations can be 
identified in which specific mutations explain a large proportion of the total mutations 
observed in a population. These and other such examples suggest that targeted mutation 
testing panels which include specific mutations could be developed for use in specific 
populations. Finally, we focused on female BRCA1 and BRCA2 mutation carriers in this 
report. However, the growing knowledge about BRCA1 and BRCA2-associated cancers in 
men, particularly prostate cancer (Ostrander and Udler, 2008; Pritchard, et al., 2016), 
suggests that the information presented herein will also have value in genetic testing of men.
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